9082 EAHAD 2021 Conference Coverage

3. What is your role in the care of individuals with hemophilia? Select all that apply *This question is required.

• Physician involved in direct patient care (management and monitoring of bleeding risk)
• Investigator in clinical trials of patients with hemophilia
• Perform assays/assessments in a specialized coagulation laboratory
• Physical, occupational, and/or mental health therapy
• Basic research related to hemophilia, but not related to patient care
• Patient education
• Other, please specify Please enter an 'other' value for this selection.

6. Please rate your ability BEFORE the activity *This question is required.

Space Cell	0 - Not Relevant	1 - Low	2	3	4	5 - High
KNOWLEDGE of the characteristics of current clinical trials in gene therapy for both hemophilia A and hemophilia B:	KNOWLEDGE of the characteristics of current clinical trials in gene therapy for both hemophilia A and hemophilia B:: 0 - Not Relevant	KNOWLEDGE of the characteristics of current clinical trials in gene therapy for both hemophilia A and hemophilia B:: 1 - Low	KNOWLEDGE of the characteristics of current clinical trials in gene therapy for both hemophilia A and hemophilia B:: 2	KNOWLEDGE of the characteristics of current clinical trials in gene therapy for both hemophilia A and hemophilia B:: 3	KNOWLEDGE of the characteristics of current clinical trials in gene therapy for both hemophilia A and hemophilia B:: 4	KNOWLEDGE of the characteristics of current clinical trials in gene therapy for both hemophilia A and hemophilia B:: 5 - High
ABILITY to describe the safety and efficacy results for clinical trials of gene therapy in patients with hemophilia A and hemophilia B:	ABILITY to describe the safety and efficacy results for clinical trials of gene therapy in patients with hemophilia A and hemophilia B:: 0 - Not Relevant	ABILITY to describe the safety and efficacy results for clinical trials of gene therapy in patients with hemophilia A and hemophilia B:: 1 - Low	ABILITY to describe the safety and efficacy results for clinical trials of gene therapy in patients with hemophilia A and hemophilia B:: 2	ABILITY to describe the safety and efficacy results for clinical trials of gene therapy in patients with hemophilia A and hemophilia B:: 3	ABILITY to describe the safety and efficacy results for clinical trials of gene therapy in patients with hemophilia A and hemophilia B:: 4	ABILITY to describe the safety and efficacy results for clinical trials of gene therapy in patients with hemophilia A and hemophilia B:: 5 - High
ABILITY to recommend appropriate patients for ongoing and emerging hemophilia gene therapy trials:	ABILITY to recommend appropriate patients for ongoing and emerging hemophilia gene therapy trials:: 0 - Not Relevant	ABILITY to recommend appropriate patients for ongoing and emerging hemophilia gene therapy trials:: 1 - Low	ABILITY to recommend appropriate patients for ongoing and emerging hemophilia gene therapy trials:: 2	ABILITY to recommend appropriate patients for ongoing and emerging hemophilia gene therapy trials:: 3	ABILITY to recommend appropriate patients for ongoing and emerging hemophilia gene therapy trials:: 4	ABILITY to recommend appropriate patients for ongoing and emerging hemophilia gene therapy trials:: 5 - High

7. Please rate your ability AFTER the activity *This question is required.

Space Cell	0 - Not Relevant	1 - Low	2	3	4	5 - High
KNOWLEDGE of the characteristics of current clinical trials in gene therapy for both hemophilia A and hemophilia B:	KNOWLEDGE of the characteristics of current clinical trials in gene therapy for both hemophilia A and hemophilia B:: 0 - Not Relevant	KNOWLEDGE of the characteristics of current clinical trials in gene therapy for both hemophilia A and hemophilia B:: 1 - Low	KNOWLEDGE of the characteristics of current clinical trials in gene therapy for both hemophilia A and hemophilia B:: 2	KNOWLEDGE of the characteristics of current clinical trials in gene therapy for both hemophilia A and hemophilia B:: 3	KNOWLEDGE of the characteristics of current clinical trials in gene therapy for both hemophilia A and hemophilia B:: 4	KNOWLEDGE of the characteristics of current clinical trials in gene therapy for both hemophilia A and hemophilia B:: 5 - High
ABILITY to describe the safety and efficacy results for clinical trials of gene therapy in patients with hemophilia A and hemophilia B:	ABILITY to describe the safety and efficacy results for clinical trials of gene therapy in patients with hemophilia A and hemophilia B:: 0 - Not Relevant	ABILITY to describe the safety and efficacy results for clinical trials of gene therapy in patients with hemophilia A and hemophilia B:: 1 - Low	ABILITY to describe the safety and efficacy results for clinical trials of gene therapy in patients with hemophilia A and hemophilia B:: 2	ABILITY to describe the safety and efficacy results for clinical trials of gene therapy in patients with hemophilia A and hemophilia B:: 3	ABILITY to describe the safety and efficacy results for clinical trials of gene therapy in patients with hemophilia A and hemophilia B:: 4	ABILITY to describe the safety and efficacy results for clinical trials of gene therapy in patients with hemophilia A and hemophilia B:: 5 - High
ABILITY to recommend appropriate patients for ongoing and emerging hemophilia gene therapy trials:	ABILITY to recommend appropriate patients for ongoing and emerging hemophilia gene therapy trials:: 0 - Not Relevant	ABILITY to recommend appropriate patients for ongoing and emerging hemophilia gene therapy trials:: 1 - Low	ABILITY to recommend appropriate patients for ongoing and emerging hemophilia gene therapy trials:: 2	ABILITY to recommend appropriate patients for ongoing and emerging hemophilia gene therapy trials:: 3	ABILITY to recommend appropriate patients for ongoing and emerging hemophilia gene therapy trials:: 4	ABILITY to recommend appropriate patients for ongoing and emerging hemophilia gene therapy trials:: 5 - High

8. Do you intend to make changes or apply new knowledge to your practice as a result of this activity? *This question is required.

• Yes*
• I’m possibly considering changes*
• This activity affirms what I already do in practice
• No, I do not intend to make any changes

If you answered yes or possibly considering changes, please check off what you intend to do differently or incorporate into your clinical management of patients as a result of this educational activity. *This question is required.

• Review the results of clinical studies that have evaluated the safety and efficacy of gene therapy for hemophilia
• Stay up-to-date with new developments and concerns related to gene therapy for patients with hemophilia
• Discuss gene therapy in the context of other therapies for hemophilia with peers and colleagues
• Begin to identify patients with hemophilia who are candidates for gene therapy
• Other, please specify Please enter an 'other' value for this selection.